Pfizer’s Drug for Rare Neuropathology Get Approved in EU, Not US

Pfizer’s Vyndaqel (tafamidis) was approved by the European Commission for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressive and fatal neurodegenerative disease affecting approximately 8,000 patients worldwide. Vyndagel was shown to be efficacious in delaying peripheral neurologic impairment as well as alleviating the digestive problems associated with the disease. It is expected to be launched in Europe by early 2012 but approval in the US will require additional data requested by the FDA in April.

Click here to read more.

Share this: